Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia
- PMID: 36068638
- PMCID: PMC9446556
- DOI: 10.1186/s13075-022-02901-y
Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia
Abstract
Background: Patients with immune thrombocytopenia (ITP) have a risk of developing systemic lupus erythematosus (SLE). We sought to examine the clinical characteristics of patients with primary ITP who later developed SLE and identified the risk factors for the development of SLE.
Methods: We retrospectively examined patients who were diagnosed with primary ITP at a tertiary hospital between August 2001 and November 2019. We compared the clinical characteristics according to the development of SLE. Logistic regression analysis was performed to identify the factors associated with the development of SLE.
Results: Of 130 patients with primary ITP, 10 (7.7%) were later diagnosed with SLE during follow-up (median, 30 months [IQR, 15.5-105]). The presence of skin bleeding, organ bleeding, lymphocytopenia, anemia, and antinuclear antibody (ANA) positivity (≥ 1:160) were more common among patients who later developed SLE than did those who did not develop SLE. Multivariate analysis showed that young age (< 40 years; odds ratio [OR], 6.307 [95% confidence interval (CI), 1.114-34.908]; P = 0.035), organ bleeding (OR, 13.672 [95% CI, 2.437-76.689]; P = 0.003), and ANA positivity (1:160; OR, 6.638 [95% CI, 1.399-31.504]; P = 0.017) were significantly associated with the development of SLE.
Conclusions: Young age (< 40 years), organ bleeding, and ANA positivity (≥ 1:160) were risk factors for the development of SLE in patients with primary ITP. Close follow-up is needed to detect the development of SLE in patients with ITP and the abovementioned risk factors.
Keywords: Antinuclear antibody; Immune thrombocytopenia; Organ bleeding; Systemic lupus erythematosus; Thrombocytopenia.
© 2022. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis.Autoimmun Rev. 2023 Apr;22(4):103297. doi: 10.1016/j.autrev.2023.103297. Epub 2023 Feb 11. Autoimmun Rev. 2023. PMID: 36781038 Free PMC article.
-
Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.Ann Hematol. 2022 Jul;101(7):1447-1456. doi: 10.1007/s00277-022-04836-5. Epub 2022 May 9. Ann Hematol. 2022. PMID: 35532821
-
Incidence and risk factors of systemic lupus erythematosus in patients with primary immune thrombocytopenia: a systematic review and meta-analysis.PeerJ. 2024 Apr 22;12:e17152. doi: 10.7717/peerj.17152. eCollection 2024. PeerJ. 2024. PMID: 38666084 Free PMC article.
-
Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura.Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):657-9. doi: 10.1002/pbc.20970. Pediatr Blood Cancer. 2006. PMID: 16933242
-
Prognostic Factors for Chronic Thrombocytopenia in Systemic Lupus Erythematosus with Immune Thrombocytopenia.Acta Haematol. 2025;148(3):280-288. doi: 10.1159/000540192. Epub 2024 Jul 29. Acta Haematol. 2025. PMID: 39074444
Cited by
-
Refractory Acquired Amegakaryocytic Thrombocytopenia with Rapid Progression to Aplastic Anaemia in SLE.Mediterr J Rheumatol. 2023 Aug 11;34(4):537-543. doi: 10.31138/mjr.110823.raa. eCollection 2023 Dec. Mediterr J Rheumatol. 2023. PMID: 38282948 Free PMC article.
-
Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry.Arthritis Res Ther. 2024 Dec 27;26(1):229. doi: 10.1186/s13075-024-03460-0. Arthritis Res Ther. 2024. PMID: 39731190 Free PMC article.
-
Immune thrombocytopenia in patients with systemic lupus erythematosus.Clin Rheumatol. 2025 Jan;44(1):97-104. doi: 10.1007/s10067-024-07235-5. Epub 2024 Dec 4. Clin Rheumatol. 2025. PMID: 39627479
-
A Predictive Model for Treatment Effectiveness in Severe Primary Immune Thrombocytopenia during Pregnancy: A Retrospective Study in a Tertiary Critical Maternity Referral Center.Gynecol Obstet Invest. 2025;90(2):153-164. doi: 10.1159/000541721. Epub 2024 Oct 5. Gynecol Obstet Invest. 2025. PMID: 39369706 Free PMC article.
-
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study.Arthritis Res Ther. 2024 Mar 12;26(1):67. doi: 10.1186/s13075-024-03305-w. Arthritis Res Ther. 2024. PMID: 38475924 Free PMC article.
References
-
- Nikolopoulos D, Kostopoulou M, Pieta A, Karageorgas T, Tseronis D, Chavatza K, et al. Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort. Lupus. 2020;29:514–522. doi: 10.1177/0961203320908932. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical